Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000415021

Medchemexpress LLC Gypenoside XLIX | 94987-08-3 | 1047.23 | 20 MG
SDP

Catalog No. 5000415021
Encompass_Preferred

Gypenoside XLIX is a multifunctional bioactive compound isolated from Gynostemma pentaphyllum. It acts as a PPAR-α agonist and binds to SIRT1. It inhibits TLR4-mediated NF-κB signaling pathway activation, reduces ROS accumulation, and alleviates hepatic inflammatory injury. It targets SIRT1 to block YAP-NLRP3 activation, improving sepsis-induced cardiomyopathy. The compound is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis, and chronic inflammation.

  • Acts as a PPAR-α agonist
  • Inhibits TLR4-mediated NF-κB signaling pathway
  • Reduces ROS accumulation
  • Alleviates hepatic inflammatory injury
  • Targets SIRT1 to block YAP-NLRP3 activation
  • Prevents acute kidney injury

Catalog No. 50-004-15021 Supplier Medchemexpress LLC Supplier No. HYN199020MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Gypenoside XLIX is a multifunctional bioactive compound isolated from Gynostemma pentaphyllum. It acts as a PPAR-α agonist and binds to SIRT1. It inhibits TLR4-mediated NF-κB signaling pathway activation, reduces ROS accumulation, and alleviates hepatic inflammatory injury. It targets SIRT1 to block YAP-NLRP3 activation, improving sepsis-induced cardiomyopathy. The compound is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis, and chronic inflammation.

  • Acts as a PPAR-α agonist
  • Inhibits TLR4-mediated NF-κB signaling pathway
  • Reduces ROS accumulation
  • Alleviates hepatic inflammatory injury
  • Targets SIRT1 to block YAP-NLRP3 activation
  • Prevents acute kidney injury

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.